Featured Featured 12:00 - 13:00 PDT IS01: Join us to hear thought leaders discuss a newly approved combination therapy that includes RYBREVANT® (amivantamab-vmjw)
Featured Featured 14:30 - 15:30 PDT IS06: Do We Have Sea Change in Small Cell Lung Cancer? What Recent Clinical Trial Data Tell Us About Treatment Decision-Making in Real World Settings, What’s Next for Emerging Novel Strategies
Featured Featured 12:30 - 13:30 PDT IS12: What’s Next for HER2- and Trop2-Directed ADCs in Lung Cancer: How Emerging Trial Data Will Impact Our Clinics Today and Tomorrow…
Featured Featured 18:30 - 19:30 PDT IS13: Accelerating Treatment Initiation with Next-Day NGS: Insights from a Multidisciplinary Collaboration Program in Precision Oncology
Featured Featured 18:15 - 19:15 PDT IS17: Lung Cancer Tumor Board®: Enhancing Precision Medicine in NSCLC Through Advancements in Molecular Testing and Optimal Therapy Selection
Featured Featured September 10 @ 18:00 - September 12 @ 15:00 PDT The Implications of Recent Data Sets for the Current and Future Management of Lung Cancer
